

## **RESPIRI'S CONTINUED LEADERSHIP IN ASTHMA MONITORING**

Respiri's focus is on home monitoring consumer products that provide an objective measure of wheeze, the primary symptom of asthma.

Peak industry bodies such as the UK Asthma Association are now enthusiastically embracing the importance of home monitoring digital technology in asthma management. Asthma UK Chief Executive, Kay Boycott, recently said: "Digital health tech is likely to be the game changer that transforms current asthma management and the patient-doctor relationship".

### **TWO CLEAR MARKET SEGMENTS EMERGING IN DIGITAL RESPIRATORY HEALTH**

The digital health market for respiratory products is now undergoing considerable change with the entry of new prescription and diagnostic products. This is positive for our industry.

The distinguishing characteristic of most successful medical devices is the provision of objective measures for use by patients, carers and their health professionals.

#### **Monitoring products for consumers to improve self-management of asthma**

There is nothing on the market like AirSonea for consumers with asthma. An over the counter product, without the need for prescription, AirSonea provides an objective measure of wheeze and replaces outdated, difficult to use and unreliable peak flow meters.

AirSonea is simple, requires no effort and provides a number the user can understand, just as a thermometer provides a number. AirSonea, is for asthma what a thermometer is for temperature.

#### **Diagnostic and prescription products**

Products in this group aim to help medical and healthcare professionals in the diagnosis, treatment and management of respiratory disease. These products include drug delivery smart inhalers, spirometry and algorithm technology.

Traditionally, this segment has slow adoption rates, requires broad physician acceptance and involves a complex regulatory pathway as there is no single reliable test ('gold standard') or standardised diagnostic criteria for asthma. The diagnosis of asthma in adults needs to be based on a patient's history, a physical examination, consideration of other diagnoses and documentation of variable airflow limitation.

### **PARTNERSHIPS**

Respiri's core business remains the continued development of world leading software that enables consumers to detect and objectively measure wheeze. The company will join with partners in the manufacture of leading edge, best in class components for the capture and transmission of breath sounds.

Following the successful University of Chicago Research Study that confirmed AirSonea's ability to reliably detect asthma wheezing, Respiro is using the AirSonea device as a prototype to demonstrate our capability in discussions with potential partners.

Respiro Limited Chairman, Leon L'Huillier, said: "the Asthma UK approach is a very positive development for the company, given the size of the UK market and the clinical research on Respiro's wheeze detection and measurement technology undertaken and published by leading UK physicians and scientists. The UK continues to be one of the key markets for partnership opportunities."

For and on behalf of the Board;



Peter Vaughan  
Company Secretary

**Ph: 1800 476 632**